Lymphoma Diagnosis
Lymphoma Diagnosis
In most cancers the diagnosis and the staging are the two answers that determine treatment. In lymphoma there is a third, and it is the one that is easiest to lose: the subtype. Diffuse large B-cell lymphoma and follicular lymphoma can look similar on a scan and behave completely differently, and the difference is established by examining the architecture of a whole lymph node. That is why the first step in this pathway is a small operation rather than a test.
Why the whole node is removed
A lymph node is not a bag of cells; it is an organised structure. Its cortex contains follicles where B cells proliferate, its medulla contains plasma cells and macrophages, and the way those populations are arranged is what distinguishes one lymphoma subtype from another. A core needle removes a column through that structure. It may retrieve diagnostic cells, but it destroys the relationships that would have been used to classify them — which is why a needle result is often reported as suspicious, or as a diagnosis that cannot be subclassified.
The procedure itself is minor. Under local anaesthetic, an incision is made over the chosen node, the node is removed intact through it, and the wound is closed. It is performed as a day case in most cases. The choice of which node to remove follows three preferences: the largest, the most accessible, and one that has not previously been treated with radiotherapy. A groin node is easiest to reach but most likely to show reactive changes from the skin and leg, so a neck or axillary node is often preferred when both are enlarged.
Two points are worth knowing in advance. Steroids mask the diagnosis: because they kill lymphocytes, a course given for suspected inflammation can shrink the node and make the biopsy unreadable. Unless the clinical situation is urgent, steroids are deferred until after the biopsy has been taken; where an emergency such as airway compression requires them, the biopsy is arranged at the same time rather than after the course. And because the tissue is consumed by the various tests, the wax block is kept — if a second opinion is sought later, it is the block that is sent, not a second biopsy.
Immunophenotyping: naming the subtype
Once the tissue is available, the diagnosis is made by identifying the proteins on the surface and inside the cells. This is the step that converts "abnormal lymphocytes" into a named disease, and it is performed as a standard panel rather than one test at a time:
- Lineage markers — CD20, CD79a and PAX5 identify a B-cell lymphoma; CD3 and CD5 identify a T-cell lymphoma; CD56 and CD30 appear in particular subtypes.
- Subtype-defining markers — CD10, BCL6 and MUM1 separate the germinal-centre from the activated B-cell forms of diffuse large B-cell lymphoma; cyclin D1 is characteristic of mantle cell lymphoma; ALK separates the two forms of anaplastic large-cell lymphoma.
- Proliferation — the Ki-67 index shows what proportion of cells are dividing, which distinguishes an indolent from a rapidly growing disease.
- Clonality — testing for a single rearranged immunoglobulin or T-cell receptor gene confirms that the population is a clone, which is decisive when the appearance is ambiguous or when lymphoma is suspected in the skin.
- Gene rearrangements — fluorescence in situ hybridisation for MYC, BCL2 and BCL6 identifies high-grade B-cell lymphoma, in which two or three of these rearrangements occur together.
- Epstein-Barr virus — detected by in-situ hybridisation, and relevant in extranodal NK/T-cell lymphoma and in lymphoma in immunosuppressed patients.
The exact panel is chosen by the pathologist from what the biopsy shows, so it is not a fixed list. For a patient the conclusion is direct: the report should give the full subtype name, and if it says only “non-Hodgkin lymphoma” or “B-cell lymphoma, not otherwise specified”, that is a prompt to ask whether the tissue was adequate and whether a specialist review is needed. Having a haemato-pathologist review the block a second time is a step that costs little and has a real chance of changing the treatment recommendation.
Imaging and laboratory tests
Staging tests are chosen to answer two questions: where the disease is, and whether the patient can safely receive the treatment that the subtype calls for. The second question is the one patients tend to overlook:
- FDG-PET/CT — the primary staging investigation for most lymphomas, combining a functional scan that shows where the tracer is taken up with a CT that shows the anatomy. It is also repeated partway through treatment to assess response.
- Contrast CT of the neck, chest, abdomen and pelvis — used where PET is not available, or alongside it to measure the dimensions of a mass.
- MRI or a lumbar puncture — for the central nervous system, which is imaged or sampled when the subtype, the site of disease or the intended regimen makes involvement likely.
- Blood count with a differential, LDH and uric acid — LDH rises with tumour turnover and is part of the prognostic indices; uric acid identifies patients who need protection against tumour lysis when treatment begins.
- Liver and kidney function — several drugs used in lymphoma are cleared by the liver or the kidney, and doses are adjusted accordingly.
- Echocardiogram and an electrocardiogram — before regimens containing an anthracycline, which include the standard first-line treatments for aggressive B-cell lymphoma.
- Hepatitis B and C and HIV testing — because rituximab can reactivate hepatitis B, which is preventable with an antiviral given in advance, and because HIV changes the management of the lymphoma itself.
Two of these need emphasis. Hepatitis B screening before an antibody-based regimen is not optional: reactivation can cause fulminant hepatitis, and it is preventable by starting antiviral treatment before the lymphoma treatment rather than waiting for the liver enzymes to rise. And the baseline echocardiogram decides whether the standard regimen can be used at all — reduced cardiac function may require the anthracycline dose to be adjusted, or a different regimen entirely, and that has to be settled before the first cycle rather than after the second.
Bone marrow biopsy
A bone marrow biopsy was once part of the routine work-up for every lymphoma. It is now used selectively, because PET-CT has replaced it for staging in FDG-avid subtypes — a scan can show marrow involvement that a biopsy taken from one site might miss. It is still performed in defined situations:
- When the blood count is abnormal — anaemia, a low platelet count or a low white cell count suggests the marrow is involved, and the biopsy describes what is happening there.
- In subtypes that characteristically involve the marrow — follicular lymphoma, mantle cell lymphoma, small lymphocytic lymphoma and several T-cell lymphomas.
- When the result changes the stage or the plan — for example, where marrow involvement would move the disease from an early to an advanced category.
- Before certain cell therapies and transplants, and in the assessment of cytopenias that persist after treatment.
The procedure takes a short sample of marrow from the back of the hip bone, usually under local anaesthetic with sedation, and takes about fifteen minutes; it is a diagnostic and staging tool rather than a treatment. A negative result does not exclude involvement elsewhere in the marrow — one reason it has been replaced by PET-CT in FDG-avid subtypes — whereas a positive result is definitive. It is reasonable to ask why the test is being done in your case and what the result would change; if the answer is that it would change nothing, there is a fair question to be asked about it.
Putting the stage together
Staging in lymphoma records three separate things, and a plan should state all three rather than a single number:
- The anatomical stage — stage I to IV under the Lugano classification, describing how many node regions are involved and whether organs or the marrow are affected.
- The presence or absence of B symptoms — recorded as A or B alongside the stage, and counted in the risk assessment.
- Whether the disease is bulky — a mass above roughly ten centimetres, or a mediastinal mass occupying a substantial part of the chest, which affects both the radiotherapy decision and the interpretation of response.
Those three are then combined into a risk group using an index appropriate to the subtype: the International Prognostic Index for aggressive B-cell lymphoma, which weighs age, LDH, performance status, stage and the number of involved sites outside the nodes; the follicular index for follicular lymphoma; the Hodgkin score for Hodgkin lymphoma; and equivalent indices for T-cell and mantle cell disease. The index is a way of grouping patients rather than a prediction about any one of them, and it is used to decide how intensive the treatment should be and whether a scan partway through should change it.
The complete picture matters because, in this disease, reporting a stage number on its own is genuinely misleading. “Stage III” describes a distribution, not a prognosis: the same stage III can belong to a follicular lymphoma that needs only monitoring or to an aggressive lymphoma that should start treatment this week. It is reasonable to ask for the subtype, the stage, A or B, whether the disease is bulky, and which risk group applies — and then to ask what each finding changed in the plan.
Turning the findings into a plan
When the subtype and stage are known, treatment can be planned, and several things should be arranged before the first cycle rather than discovered during it:
- A written treatment calendar — the regimen, the number of cycles, the drugs in it, and the date of the interim and end-of-treatment scans.
- Fertility preservation — discussed and acted on before treatment begins for patients of reproductive age, since some regimens affect fertility and the options take time to arrange.
- Antiviral prophylaxis where indicated, and vaccination advice, including avoiding live vaccines during and after treatment.
- Tumour lysis protection — fluids and a drug that lowers uric acid, started before treatment in high-turnover disease, because the first cycle carries the greatest risk.
- Central venous access — planned where the regimen requires infusions over days or where veins are difficult.
- The response criteria stated in advance — what the interim scan would need to show for treatment to continue unchanged, and what result would lead to intensification or a change of regimen.
Two of these are commonly underrated. Fertility preservation takes weeks to arrange and cannot be done once treatment has started, so it belongs in the first conversation rather than at some later point. And writing down in advance what the interim scan is meant to decide removes the ambiguity of a report that says there has been improvement without stating a threshold. Send the biopsy report and the block, the immunophenotyping results, the PET-CT images, the blood results and the treatment already given, and the written assessment is returned within 48 hours of the file being complete.